<DOC>
	<DOCNO>NCT02063022</DOCNO>
	<brief_summary>Controlled , randomized phase III study , intent optimize treatment metastatic Ewing Sarcoma . The patient randomize 2 arm : standard treatment vs intensive treatment . Both arm receive induction treatment follow surgery ( wherever possible ) and/or radiotherapy . The maintenance treatment different basis response induction treatment ( good poor )</brief_summary>
	<brief_title>Efficacy Dose Intensification Patients With Non-metastatic Ewing Sarcoma</brief_title>
	<detailed_description>Eligible patient non metastatic Ewing 's Sarcoma randomize 2 different arm : standard treatment arm A ( base ISG/SSG III protocol ) experimental arm B ( chemotherapy dose intensification shorter length treatment ) . Both arm receive induction treatment high dose intensity doxorubicin ifosfamide Arm B . After induction treatment patient undergo local treatment ( surgery and/or radiotherapy ) follow maintenance therapy . The maintenance therapy different arm , within arm , basis response ( histologically evaluate ) pre-local treatment therapy . Maintenance Arm A : Poor responder undergo stem cell apheresis reinfusion treatment high dos Busulfan Melphalan 25 week . Good responder receive 6 drug maintenance treatment 37 week ( per standard ISG/SSG III protocol ) Maintenance Arm B : Poor responder undergo stem cell apheresis reinfusion intensify treatment high dos Busulfan Melphalan ( 25 week ) . Good responder receive maintenance treatment 25 week The primary aim study assess Event Free Survival ( EFS ) expect similar arm The secondary objective : To assess induction treatment Arm B able increase percentage good responder compare receive standard treatment . To assess toxicity Quality Life relate chemotherapy treatment</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Inclusion Criteria Ewing Sarcoma PNET diagnosis centrally confirm Age â‰¤ 40 year Absence evident metastasis lung meet &lt; 0.5 cm Presence skip metastasis bone compartment primary tumor consider local disease metastatic . Adeguate bone marrow , hepatic renal function Left Ventricular Ejection Fraction &gt; 50 % No primary Ewing Sarcoma treatment ( chemotherapy and/or radiotherapy ) Voluntarily sign informed consent form Radiological histological documentation available central review . Exclusion Criteria Presence lung extrapulmonary lesion Bone Marrow involvement In case chest disease : presence plural effusion Elapsed time histological diagnosis chemotherapy start , 4 week Any medical contraindication use study drug Any psychological social condition compromise protocol compliance and/or followup Previous malignancy ( exclude situ cervix carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non metastatic Ewing 's Sarcoma</keyword>
</DOC>